NORCROSS,SpectRx has taken another step toward bringing to market a non-invasive device for the detection of cervical cancer.
The pre-production device still has to be approved for use by the Food and Drug Administration.
According to SpectRx, the device uses light reflected from the cervix to identify cancer and pre-cancer tissue. No tissue sample or laboratory analysis is required.
So far, more than 1,600 women have been tested with various prototypes. The company hopes to launch a clinical trial this year.
SpectRX: www.spectrx.com
